Basking Biosciences (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- February 01, 2024
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $55,000,000
Company Info
- Founders
- Richard Shea
- Company Description
- Basking Biosciences is a clinical-stage biopharmaceutical company focused on developing a rapid-onset, short-acting thrombolytic drug for reopening blocked arteries, with the ability to quickly reverse its activity in case of bleeding complications. Their lead drug candidate, BB-031, utilizes RNA aptamer technology to target von Willebrand Factor, aiming to enhance safety and effectiveness in acute revascularization therapy.
- Market
- Acute thrombosis treatment
- Location
- Columbus, Ohio, USA
- Coinvestors
- ARCH Venture Partners, Insight Partners, Longview Ventures, Platanus, Rev1 Ventures, RTW Investments, Solas Bioventures, The Ohio State University